抑制甘氨酸降解可以防止艾滋病毒引起的炎症和认知障碍
Leila B Giron1,2,3, Alejandra Borjabad4, Eran Hadas4
1Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
bioRxiv : the preprint server for biology
|December 3, 2025
概括
促炎症的甘氨酸降解,标志着酸和银河糖的损失,驱动HIV的认知障碍. 在HIV模型中,用sianlidase抑制剂抑制这个过程逆转了炎症和记忆缺陷.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 葡萄糖生物学 葡萄糖生物学
背景情况:
- 慢性病毒感染,如艾滋病毒,与过早衰老和认知障碍有关.
- 与艾滋病毒相关的认知障碍 (HIV-CI) 背后的确切机制尚未完全理解.
研究的目的:
- 确定与艾滋病毒相关的认知障碍 (HIV-CI) 的关键分子贡献者.
- 调查糖降解在HIV-CI中的作用,并探索潜在的治疗干预措施.
主要方法:
- 分析艾滋病毒感染人类队列中的甘氨酸变化 (酸,银河糖).
- 使用人性化的小鼠模型和Eco-HIV模型进行体内研究.
- 药理上抑制使用化酶抑制剂的甘氨酸降解.
主要成果:
- 退化性甘氨酸变化,表明过早衰老,在艾滋病毒-CI的个体中普遍存在,特别是女性.
- 这些变化与艾滋病毒感染者的认知功能较差有关.
- 化酶抑制剂在动物模型中减轻了艾滋病毒引起的炎症,免疫激活,衰老和记忆缺陷.
结论:
- 促炎性甘氨酸降解是艾滋病毒相关认知障碍的一个重要因素.
- 通过保护性疗法准甘氨酸降解提供了一种有前途的策略,用于对抗HIV和潜在的其他病毒感染的炎症,过早衰老和认知衰退.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


